Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Jyong Biotech Announces Proposed Texas Facility to Support Potential Commercialization of Its Drug CandidatesJyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced that it plans to establish a potential new manufacturing facility and U.S. operations center in Texas. The initiative is intended to support the Company’s U.S. operations and position it for the potential future commercialization of its proprietary investigational drug candidates, if approved.
- Nautilus Biotechnology Inc.Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter 2026 before market open on Tuesday, October 27, 2026.
- Xeris Biopharma Holdings, Inc.Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific MeetingsClinical and scientific data presentations in support of Gvoke® (glucagon) injection, Recorlev® (levoketoconazole), and the investigational XP-8121 program underscore Xeris's leadership in endocrinology, including the treatments for Severe Hypoglycemia, Cushing's Syndrome, and Hypothyroidism CHICAGO, October 15, 2026 --(
- Global Antibody Drug Conjugates (ADC) Market Forecast 2026-2030 by Cancer, Payload, Target, Product, User, and Region | Pipeline Growth and Licensing Deals Fuel ExpansionMap ADC opportunities across cancer type, payload, target, product, user and country, with insights on 100 companies, strategic plans, risks and growth drivers.
- insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and CardiomyopathiesCompanies: AstraZenecaCollaboration applies insitro's Virtual Human causal AI discovery platform to two diseases defined by patient heterogeneity and high unmet medical need insitro to receive $40 million upfront and up to approximately $1.46 billion in potential discovery, development, and commercial milestones, and tiered royalties SOUTH SAN
- LTR PharmaRoxus® ED Nasal Spray Now Available in the U.S.: Peak Blood Levels in About 10 Minutes, Not an HourAvailable by prescription through telemedicine partner Mavrox.com/Roxus . LTR Pharma Limited (ASX: LTP), the Australian pharmaceutical company, today announced that Roxus® is now available to men across the U.S. Roxus is a prescription nasal spray for erectile dysfunction (ED) that delivers vardenafil, the same type of ED medicine as Viagra®, used in tablets for more than 20 years, through LTR's pro
- ORGANA Highlights In-House Manufacturing and GMP PracticesSpringville, UT Thursday Oct 15, 2026 @ 5:00 AM Eastern — ORGANA, a Utah-based wellness company offering mineral and botanical products, is highlighting an important distinction in its business model: the company manufactures its products in-house, following Good Manufacturing Practices (GMP), rather than relying on third-party contract manufacturers. While many wellness brands outsource manufacturing to specialized production facilities, ORGANA maintains direct responsibility for its manufacturing operations. This approach gives the company greater oversight of production processes, quality-control procedures and the consistency of its product portfolio. For ORGANA, in-house manufacturing is part of a broader commitment to maintaining control over how its products are produced, from raw materials through finished goods. "There's a difference between selling a product with your name on it and actually manufacturing that product yourself," said Larry Mills, CEO of ORGANA. "We've chosen to handle our own manufacturing because we want direct oversight of the products we put into the marketplace. Quality is something we take seriously throughout the process." ORGANA follows GMP practices in its manufacturing operations, emphasizing established production procedures, quality controls and consistency. By keeping manufacturing in-house, the company can oversee its processes directly rather than depending on outside manufacturers to manage production on its behalf. The company's manufacturing approach supports a portfolio of mineral and botanical wellness products, including: Plant-Derived Trace Minerals - A liquid mineral product sourced from an ancient mineral deposit in Utah, offering naturally occurring trace minerals in a convenient format. Liquid Oxygen 125 PPM - A liquid product that is part of ORGANA's broader wellness portfolio. Essiac Tea - A botanical product based on a traditional herbal blend. Pomegranate Mineral Drink - A pomegranate-flavored liquid mineral product offering another way to incorporate minerals into everyday routines. These products reflect ORGANA's focus on mineral and botanical formulations, with in-house manufacturing providing a consistent approach to production oversight across the portfolio. Maintaining its own manufacturing operations also allows ORGANA to keep product development and production closely connected. As the company continues to grow its retail presence, this operating model remains an important part of its approach to quality and customer confidence. "Consumers don't always know who actually makes the products they're buying," Mills added. "For us, manufacturing isn't something we've handed off to another company. It's part of who we are and how we operate." ORGANA products are available through Amazon, Walmart and OneLavi.com, providing consumers with access to the company's mineral and botanical wellness portfolio. As ORGANA continues expanding its presence in the U.S. marketplace, the company plans to maintain its focus on in-house manufacturing, GMP practices and direct oversight of production. About ORGANA International Founded in 1997, ORGANA International is a wellness company committed to delivering natural, bioavailable products that help people live healthier lives. From trace minerals and liquid oxygen to magnesium creams and detoxification teas, ORGANA’s product line is designed to restore vital elements often missing in modern lifestyles. Headquartered in Springville, Utah, ORGANA is a customer-first company with a 5-star BBB rating and nearly three decades of dedication to natural wellness. FDA Disclaimer These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
- Sunnybrook Announces the Marg Gillespie Precision Oncology Centre to Advance Personalized Cancer Care$29 million in philanthropic support is the reason Sunnybrook will create a purpose-built clinical trials hub to accelerate discovery, advance personalized cancer care and increase access to emerging therapies for future patients. TORONTO, October 15, 2026--Sunnybrook Health Sciences Centre is proud t
- TNT Says Don't Wait Until January to Reset Your Fitness RoutineBoca Raton, Florida Thursday Oct 15, 2026 @ 4:00 AM Eastern — Coming off its recent participation at ECRM, where True Nutrition Technology (TNT) featured its German sports nutrition portfolio during meetings with U.S. retail buyers, the company is turning its attention to a familiar seasonal fitness pattern: waiting until January to start again. TNT says fall offers an opportunity to do the opposite. Rather than allowing changing schedules, shorter days and the approaching holiday season to interrupt established fitness routines, athletes and active consumers can use the final months of the year to focus on consistency and enter January with momentum already established. "January gets a tremendous amount of attention in the fitness industry, but there's no reason to wait for a date on the calendar to get serious about your routine," said Markus Himmelstoss, Managing Director of TNT. "Fall can be a great time to reset, establish consistency and build habits that are already in place when the new year arrives." Fall Brings a Different Training Rhythm For many people, the transition from summer to fall changes how and when they train. Daylight hours become shorter, temperatures change, vacations end, school schedules return, and outdoor activities may begin shifting indoors. At the same time, the approaching holiday season can make regular training more difficult to maintain. TNT believes adapting to those changes is more useful than treating them as a reason to put fitness goals on hold until January. "Consistency doesn't mean every workout or every week has to look exactly the same," Himmelstoss said. "Schedules change. Seasons change. The important thing is finding a routine that works with those changes instead of continually stopping and starting." Building the Routine Before January The New Year's fitness surge has become an annual tradition, with January often associated with new gym memberships, new training programs and renewed attention to nutrition. TNT's message this fall is simple: the habits people hope to begin in January can start in October. Establishing a realistic training schedule during October, November and December can allow people to experiment with workout times, adjust routines and develop greater consistency before the calendar turns to a new year. That philosophy reflects TNT's broader approach to sports nutrition and training, which emphasizes supporting an active lifestyle over time rather than focusing on short-term trends. A Portfolio Built Around Active Lifestyles TNT's portfolio includes Creapure Creatine Monohydrate, CLEAR WHEY protein isolate, Synapsensause Pre-Workout, and Game Changer, its carbohydrate and electrolyte formulation. The German brand has built a customer base of more than 500,000 consumers and is now expanding its presence in the United States. Its recent ECRM participation was part of that effort, introducing U.S. retail buyers to TNT's broader portfolio while the company continues building awareness and distribution in the American market. "Whether someone trains year-round or is trying to get back into a routine, the fundamentals don't suddenly become important on January 1," Himmelstoss said. "Our message is to start where you are, build consistency and carry that momentum into the new year." TNT products are available to U.S. consumers through Amazon and OneLavi. Where American Consumers Can Purchase TNT Products TNT Creapure® Creatine Monohydrate Powder on OneLavi TNT Synapsensause Pre-Workout "Wild Berry" Pre-Workout Booster on Amazon TNT Synapsensause Pre-Workout "Wild Berry" Pre-Workout Booster on OneLavi TNT Clear Whey Protein Isolate - Peach Iced Tea on OneLavi About TNT (True Nutrition Technology) Founded in Germany by former athletes Michael Weigl and Markus Himmelstoss, TNT (True Nutrition Technology) is a leading sports nutrition brand trusted by more than 500,000 customers. Since 2012, TNT has produced premium supplements under strict German quality standards, with every product independently lab-tested for safety, purity, and transparency. TNT’s core product lineup includes Creatine Monohydrate with Creapure®, CLEAR WHEY Protein, and Synapsensause Pre-Workout-three performance-focused supplements widely used by athletes to support strength, recovery, energy, and training intensity. From advanced protein blends to innovative vegan formulations, TNT develops evidence-based nutrition designed to help athletes and everyday individuals perform at their best. More than just supplements, TNT represents a passion for sport, health, and performance. Built on German precision and a culture of honesty, TNT continues to expand globally with one mission: delivering the highest quality nutrition-for us, and for you. FDA Disclaimer These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
- invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journalinvIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal
- DaltonTx awarded grant to accelerate AI-powered tuberculosis drug discoveryDaltonTx awarded grant to accelerate AI-powered tuberculosis drug discovery
- Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of potential disease-modifying treatment MTX325Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of potential disease-modifying treatment MTX325